Last reviewed · How we verify
Contrast Media
At a glance
| Generic name | Contrast Media |
|---|---|
| Sponsor | Nextrast, Inc. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Study of New Magnetic Resonance Imaging Methods of the Brain
- Baylor Infant and Toddler Biomarker of Nutrition Study
- Conventional vs Pulsed RF in Coccydynia (NA)
- A Screening Program to Improve the Early Detection of Sporadic Pancreatic Cancer in Individuals With a High-Risk of Developing Pancreatic Cancer (NA)
- Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change (PHASE2)
- Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial (PHASE2)
- NHLBI-Emory Advanced Cardiac CT Reconstruction
- Irradiation in Paediatrics: Neurocognition, Neuroimaging and Evaluation of Memory and Attention (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Contrast Media CI brief — competitive landscape report
- Contrast Media updates RSS · CI watch RSS
- Nextrast, Inc. portfolio CI